BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26153655)

  • 1. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.
    Mayado A; Teodosio C; Garcia-Montero AC; Matito A; Rodriguez-Caballero A; Morgado JM; Muñiz C; Jara-Acevedo M; Álvarez-Twose I; Sanchez-Muñoz L; Matarraz S; Caldas C; Muñoz-González JI; Escribano L; Orfao A
    Leukemia; 2016 Jan; 30(1):124-30. PubMed ID: 26153655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
    Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
    Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
    J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
    Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
    Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.
    Garcia-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Teodosio C; Sanchez-Muñoz L; Muñiz C; Muñoz-Gonzalez JI; Mayado A; Matito A; Caldas C; Morgado JM; Escribano L; Orfao A
    Blood; 2016 Feb; 127(6):761-8. PubMed ID: 26622064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CD34
    Mayado A; Teodosio C; Dasilva-Freire N; Jara-Acevedo M; Garcia-Montero AC; Álvarez-Twose I; Sánchez-Muñoz L; Matito A; Caldas C; Muñoz-González JI; Henriques A; Sánchez-Gallego JI; Escribano L; Orfao A
    Allergy; 2018 Jun; 73(6):1294-1304. PubMed ID: 29331029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
    Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
    Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and prognostic impact of
    Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Henriques A; Viñas E; Prieto C; Sánchez-Muñoz L; Caldas C; Mayado A; Matito A; Dasilva-Freire N; Orfao A; García-Montero AC
    Blood; 2019 Aug; 134(5):456-468. PubMed ID: 31151985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis.
    Söderlund S; Boey D; van Midden W; Kjellander M; Ax K; Qian H; Dahlin JS; Ungerstedt J
    J Allergy Clin Immunol; 2023 Jul; 152(1):205-213. PubMed ID: 36813186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL).
    Horny HP; Sotlar K; Stellmacher F; Valent P; Grabbe J
    J Clin Pathol; 2006 Mar; 59(3):264-8. PubMed ID: 16505276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of somatic and germline mutations on the outcome of systemic mastocytosis.
    Muñoz-González JI; Jara-Acevedo M; Alvarez-Twose I; Merker JD; Teodosio C; Hou Y; Henriques A; Roskin KM; Sanchez-Muñoz L; Tsai AG; Caldas C; Matito A; Sánchez-Gallego JI; Mayado A; Dasilva-Freire N; Gotlib JR; Escribano L; Orfao A; García-Montero AC
    Blood Adv; 2018 Nov; 2(21):2814-2828. PubMed ID: 30373888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Prognostic Impact of the
    Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Sánchez-Muñoz L; Pedreira CE; Álvarez-Twose I; Matarraz S; Morgado JM; Bárcena P; Matito A; Mayado A; Sanchez ML; Diez-Campelo M; Escribano L; Orfao A
    J Allergy Clin Immunol; 2013 Apr; 131(4):1213-24, 1224.e1-4. PubMed ID: 23403045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
    Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.